Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04287985 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of VIS649 for IgA Nephropathy
A Phase 2 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 2
- Development phase
- 155
- Enrollment target
NCT04287985: Completed Phase 2 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
NCT04287985 is a Phase 2 study that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 155 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (17% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04287985, a Phase 2 study, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 155 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of VIS649 in participants with immunoglobulin A (IgA) Nephropathy (IgAN)
Primary Outcome
The number of participants who experienced adverse events, graded by maximum severity, are presented.
Interventions
- DRUG Dose-Placebo
- DRUG Low Dose-VIS649
- DRUG Medium Dose-VIS649
- DRUG High Dose-VIS649
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2020-07-20 |
| Est. Completion | 2023-06-18 |
| Phase | Phase 2 |
What the finished NCT04287985 record still lists
NCT04287985 is an interventional study that assigns participants to a tested intervention. The registered 155 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (17% higher).
The record links to 0 conditions, and to 4 interventions - of which Dose-Placebo is the first listed.
NCT04287985 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04287985 about?
NCT04287985 is a clinical study titled "Safety and Efficacy Study of VIS649 for IgA Nephropathy". The purpose of this study is to evaluate the efficacy and safety of VIS649 in participants with immunoglobulin A (IgA) Nephropathy (IgAN)
What is the current status of trial NCT04287985?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 155 participants. The study started on 2020-07-20. Estimated completion is 2023-06-18.
What interventions are being tested in trial NCT04287985?
The interventions under investigation include: Dose-Placebo (DRUG), Low Dose-VIS649 (DRUG), Medium Dose-VIS649 (DRUG), High Dose-VIS649 (DRUG).
Who is sponsoring clinical trial NCT04287985?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04287985's enrollment target sits among peer trials
155 448th of 2000 higher than 1,553 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03223610 · 155 participants · Phase 1
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
- NCT05072483 · 155 participants
Natural History Study of CADASIL
- NCT05086497 · 155 participants · NA
WBSI Guided Personalized Delivery of TTFields
- NCT05412069 · 155 participants · NA
Trial to Evaluate Fecobionics in Fecal Incontinence (FI) (NORMAL and ABNORMAL-FI)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI